Ketamine/esketamine treatment for resistant depression in children and adolescents: a PRISMA systematic review.
European child & adolescent psychiatry February 2026 Konstantinos N Fountoulakis, Paraskevi Tatsiopoulou, Athanasios Saitis et al.
Ketamine and esketamine have been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior in adults. The current paper aimed to systematically review the available data on their efficacy in children and adolescents. The MEDLINE was searched with the keyword 'esketamine' on July 5th, 2024 (by following the PRISMA statement)....